
Opinion|Videos|December 13, 2023
How Administration of Bispecific T-Cell Engagers Has Evolved
Author(s)Justin LaPorte, PharmD, BCOP
A clinical pharmacist explains how their practice has evolved related to the administration of bispecific T-cell engagers.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5































